Swedish Cancer Institute
Oncology
Dr. Howard L. West, MD
|
|
Give Review
Howard West practices Oncology. He researched medicine at Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Howard West is a published MD. He published 25 publications, including: 'Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.' He is registered with Medicare and accepts Medicare payments.
Publications
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung Cancer: a single-group, multicentre, phase 2 trial.
- Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American S...
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer.
- Bronchioloalveolar carcinoma: not as easy as "BAC".
- Bronchioloalveolar carcinoma: the case for two Diseases.
- Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
- Myalgias and arthralgias associated with paclitaxel.
- Denosumab for prevention of skeletal-related events in patients with bone metastases from solid Tumors: incremental benefit, debatable value.
- Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's Disease.
- Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
- Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung Cancer.
- The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung Cancer.
- Cancer vaccines for the treatment and prevention of non small-cell lung Cancer.
- Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell Lung...
- Emerging approaches to advanced bronchioloalveolar carcinoma.
- Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung Cancer.
- Current standards and ongoing controversies in the management of locally advanced non-small cell lung Cancer.
- Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung Cancer: a phase II clinical trial.
- Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung Cancer.
- Molecular analysis-based treatment strategies for the management of non-small cell lung Cancer.
- Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
- Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
- Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patien...
- Maintenance therapy in non-small-cell lung Cancer.
Schools
Harvard Medical School
University Of Wa School Of Med
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Choice Health PPO
- First Health (Coventry Health Care) PPO
- Group Health Cooperative
- HealthSmart
- Humana
- Connect
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- PacificSource
- Heritage Plus
- Heritage Signature
- Principal Life
- Personal Option EPO
- Preferred Provider Network PPN
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of Washington -
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Swedish Medical Center-Cherry Hill Campus
Drug Facts
| NPI NUMBER | 1346324068 | |
| NPPES Provider LastName | WEST | |
| NPPES Provider FirstName | HOWARD | |
| NPPES Provider ZIPCode | 981043588 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 875.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 145.0 | |
| Percent Opioid Claims | 16.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346324068 |
| Last Name Of The Provider | WEST |
| First Name Of The Provider | HOWARD |
| View All |
Similar Doctors
|
|
Dr. Martin A. Cheever, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kristine J. Rinn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elihu H. Estey, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ajay K. Gopal, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. H J. Deeg, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Merav Bar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Min S. Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew S. Sandler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derek L. Stirewalt, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|